Assessing the place of nicotine vaporisers in tobacco control by Gartner, Coral & Hall, Wayne
POST-PRINT 
This is a post-print (post-refereed, final accepted) version of the manuscript that has been published 
in Tobacco Control. The citation details and the link to the final publisher version are below. 
Gartner, C. and Hall, W. (2016), Assessing the place of nicotine vaporisers in tobacco control. Tob Control 
2016;25:e1-e2 doi:10.1136/tobaccocontrol-2016-053025 
Published online: 1 April 2016. 
http://tobaccocontrol.bmj.com/content/25/e1/e1.full 
  
Title: Assessing the place of nicotine vaporisers in tobacco control 
 
 
Authors 
Coral Gartner 
School of Public Health, The University of Queensland, Public Health Building, Herston Qld 4029, 
Australia 
Email: c.gartner@uq.edu.au 
 
Wayne Hall 
Centre for Youth Substance Abuse Research, The University of Queensland, CYSAR K Floor Mental 
Health Centre, Royal Brisbane and Women’s Hospital Site, Herston, 4029 Queensland Australia  
Email: w.hall@uq.edu.au 
 
Words: 1281 
 
 
  
The substantial interest among smokers in e-cigarettes and other nicotine vaporisers has taken the 
tobacco control field by surprise and produced strongly polarised responses. Proponents see these 
products as a disruptive technology that promises to accelerate the end of tobacco smoking by 
increasing quitting and providing a safer longer term alternative to the combustible cigarette.  Their 
opponents see them as a threat to tobacco control that will allow the cigarette industry to subvert 
tobacco control policies, renormalise smoking and recruit new smokers.  
 
It has been very difficult to assess the plausibility of these radically different scenarios because the 
evidence on who uses these devices and how they are used has been mostly limited to cross-
sectional studies. Much better data from prospective studies are needed to clarify how many 
smokers are using them to quit and with what success; how many are using them as a full-time 
substitute for smoking; and how many are only using them when smoking is forbidden but otherwise 
continuing to smoke (dual use). It has also been unclear to what extent adolescents are using these 
products. Are those using them using them with or without nicotine? How many simply experiment, 
without continuing to use, and of those who do continue to use how many become smokers and 
how many of these would have done so in the absence of e-cigarettes? 
 
The tobacco control field has begun to address the evidence gap by a dramatic increase in research 
over the last five years (see figure). The current issue contains a good cross section of the type of 
studies that are being done.  
 Better measures of vaping are essential. Because of the low prevalence of vaping in earlier surveys 
some authors have defined vapers as people who have ‘ever used’ a nicotine vaporiser or used one 
in the last month. These measures over-estimate regular and current use because they include many 
infrequent users who report using vaping products out of curiosity rather than for quitting, many 
more of whom will discontinue their use compared to smokers who use them to quit smoking.1 
 
It is also essential to collect better data on the type of vaping devices that are used because the 
vaporiser market has rapidly evolved in recent years. Earlier “cigalikes” that tried to mimic the look, 
feel and taste of combustible cigarettes have been supplanted by refillable tank systems favoured by 
vapers who see vaping as a unique activity (rather than another form of smoking), complete with its 
own language (e.g. ‘vaping’, ‘sub-ohming’, ‘cloud-chasing’). The move away from cigalikes to tank 
systems has been motivated by the search for devices that deliver nicotine more efficiently and that 
allow users to customise their device and the vaping liquid such as adjusting nicotine levels and 
 
Figure 1: Publications per year including e-cigarette related terms 
 
Legend: Results of PubMed Search (*26/02/2016) for (vaping) OR 
("electronic cigarette/s") OR ("e-cigarette/s") OR ("e-cig/s") OR ("electronic 
nicotine device/s") OR ("electronic nicotine delivery system/s") 
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flavours. Tank systems are now so advanced that experienced users can achieve nicotine doses that 
rival those from cigarettes under certain conditions.2  
 
The flavouring of the e-liquid 3 4 has also evolved from replicating the tobacco taste of cigarettes to 
providing an incredible array of non-tobacco flavours. Experimenting with flavours is an integral 
experience for many vapers. The potential risks from inhaling flavourings, which are often present in 
e-liquids in concentrations around 1-4%,4 is an emerging area of research concern. Flavouring 
additives such as vanillin/ethyl vanillin and liquorice have a long history of use in tobacco cigarettes,5  
where their main health impact has been to increase the palatability of the inhaled smoke. The long-
term health effects of inhaling flavours in the absence of the harmful constituents of tobacco smoke 
has not been fully quantified. Some flavours may be relatively benign, but others, such as diacetyl, 
raise more concerns.6 Further research is needed to identify and eliminate the flavourings that are 
likely to pose the most risk to vapers.  
 
It is critical to know what smokers think about the benefits and safety of vaporisers. Do they believe 
them to be useful cessation aids or do they think that vaping could make quitting harder? Are 
nicotine vaporisers an acceptable and attractive alternative to combustible cigarettes or are they 
seen as inferior? Rooke et al 7 used qualitative interviews and focus groups to explore smokers’ and 
former smokers’ perceptions of vaping products, finding a range of divergent views. While some saw 
vaporisers as a potentially helpful cessation aid, others were sceptical about these devices’ benefits 
and safety, with some ironically preferring the certainty of the harm from smoking cigarettes to the 
uncertain benefits and risks of vaping. Over-regulation of vaping products can have the perverse 
effect of denying smokers access to a less harmful option,8 while allowing much more dangerous 
cigarettes to remain freely available. However, under-regulation may also prevent smokers who 
could benefit from switching, from doing so due to low consumer confidence in the quality of the 
devices and liquids. Finding the optimal regulatory sweet spot between prohibition and regulatory 
anarchy is a difficult task given the lack of consensus in the tobacco control community about how 
much regulation is necessary and what aspects of these products should be regulated and how.  
 
The hybrid nature of these products makes them difficult to fit within existing regulatory categories. 
The result has been divergent approaches to regulation. A vaping product may be regulated as a 
medical device/medicine for cessation use only, as a tobacco product, a general consumer good, as a 
non-tobacco recreational substance or as a poison because they contain nicotine (e.g. Australia). We 
should require evidence of efficacy and safety of devices for which therapeutic claims are made. But 
restricting smokers’ access to nicotine vaporisers only when they are approved for use as medicines 
(as in Australia) may have the unintended effect of conferring a monopoly on products owned by 
industrial entities with the capital to navigate the pharmaceutical regulatory process, such as the 
tobacco industry.9  
 
The impending FDA deeming regulations in the USA and the Tobacco Products Directive in Europe 
will affect the types of vaping products on the market. However, regulations over the sale and use of 
vaping products have already been enacted in many jurisdictions. Some states in the US10 and in 
Australia,11 have included vaping products within the definition of tobacco products in tobacco 
control legislation, thereby applying the same restrictions as apply to sale and use of cigarettes. 
Others have created vaping product specific regulations and many are yet to decide how to regulate 
sale and public use. In the absence of licensing vaping product retailers, researching the vaping 
market will require new research methods to identify these retail outlets, such as the method used 
by Kim et al12 to compile a list of vape shops by using a combination of online databases and a 
crowdsourcing Internet marketplace. 
 
Monitoring the activities of the tobacco industry in the vaping product market is and ought to be an 
active area of inquiry. Products marketed by tobacco companies in the USA have been limited so far 
to cigalike devices. They comprise previously independent brands (e.g. Blu, Green Smoke, Logic) and 
those developed by these companies (e.g. MarkTen, Vuse).13 Cigalike devices may be more attractive 
products for combustible cigarette companies to market rather than refillable tank devices, because 
advertisements featuring these products14 have the potential benefit for the tobacco industry of re-
glamourizing combustible cigarettes due to their similar appearance, which remain their main 
product.  
 
The debate about vaping has generated almost as much heat and steam as the devices themselves. 
The papers in this issue should generate robust, but, civil and constructive discussion of these 
important topics. Better research is needed to enable regulators to develop regulatory responses 
that capture the potential public health benefits of these devices while minimising the potential risks 
that some ways of promoting their use may pose to public health. 
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